23In 2008, while the clinical programme for Dexdor was ongoing, the applicant submitted an application for a paediatric investigation plan in accordance with Article 7 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ 2006 L 378, p. 1). In those circumstances, the applicant reminded the EMA of the existence of the Czech marketing authorisation for Precedex, while disputing its compliance with EU law. By letter of 5 February 2009, the EMA contacted the SUKL to request from it details regarding the date on which the Czech marketing authorisation for Precedex was granted and the compliance of that authorisation with EU law. In its reply of 20 February 2009, the SUKL stated that all the national marketing authorisations granted since 1998, such as the Czech marketing authorisation for Precedex, complied with EU law. On the basis of that reply, the EMA informed the applicant that it was not required to submit a paediatric investigation plan.